Insulin Lispro Injection

DRUG5 trials

Sponsors

Halozyme Therapeutics, Biocon Limited, The First Affiliated Hospital of Xiamen University, Tonghua Dongbao Pharmaceutical Co.,Ltd, St. Peter's Hospital, Albany, NY

Conditions

Diabetes Mellitus, Type 2Healthy VolunteersStress HyperglycemiaSurgical Site InfectionsType 1 Diabetes MellitusType 2 Diabetes

Phase 1

Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20

CompletedNCT00803972

Halozyme TherapeuticsHealthy Volunteers

Start: 2008-11-30End: 2009-08-28Updated: 2018-08-15

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Insulin (IN-105) in Type 1 Diabetes Patients

TerminatedNCT01035801

Biocon LimitedType 1 Diabetes Mellitus

Start: 2010-08-21End: 2011-03-12Updated: 2018-01-23

Phase 3

Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes

CompletedNCT05834868

Tonghua Dongbao Pharmaceutical Co.,LtdType 2 Diabetes

Start: 2022-05-06End: 2024-12-31Updated: 2025-12-22

Phase 4

Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients

CompletedNCT01776788

The First Affiliated Hospital of Xiamen UniversityDiabetes Mellitus, Type 2

Start: 2012-08-31End: 2015-02-28Updated: 2015-03-10

Unknown Phase

Perioperative Glucose Monitoring and Treatment to Reduce Risk of Surgical Site Infections and Complications

Enrolling by invitationNCT06765655

St. Peter's Hospital, Albany, NYStress Hyperglycemia, Surgical Site Infections

Start: 2024-04-09End: 2025-01-31Target: 266Updated: 2025-01-09